Skip to content

Study · Randomized controlled trial · n = 73 · 2020

3 results

Attachment anxiety moderates the effect of oxytocin on negative emotion recognition: Evidence from eye-movement data.

Wang T, Tang Q, Wu X, Chen X

Pharmacology, biochemistry, and behavior21 Aug 2020Cited by 8 (Europe PMC)

PMID32835786 (opens in a new tab)DOI10.1016/j.pbb.2020.173015 (opens in a new tab)PepBankPUB-32835786
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In healthy adults, a single dose of intranasal oxytocin increased eye gaze towards facial expressions compared with placebo.

    In plain wordsIn healthy adults, nasal oxytocin increased how much people looked at the eyes of faces compared with placebo.

    Peptide
    Oxytocin
    Outcome
    IncreaseEye gaze towards facial expressions
    Study

    n = 73

    Comparator
    Placebo
    Outcome group
    Social behavior and cognition · Nervous system and cognition
    Studied dose
    24 IU · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    Our results showed that oxytocin increased participants' eye gaze towards facial expressions.
    2 context sentences
    Summary · context
    We employed a placebo-controlled, double-blind, within-participants design.
    Summary · context
    The participants were 73 healthy individuals (41 men) who received a single dose of intranasal oxytocin (24 IU) on one occasion and a placebo dose on another occasion.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In healthy adults with high attachment anxiety, intranasal oxytocin increased eye gaze towards facial expressions compared with placebo, regardless of emotion valence.

    In plain wordsIn healthy adults with high attachment anxiety, nasal oxytocin increased looking at the eyes of faces compared with placebo.

    Peptide
    Oxytocin
    Outcome
    IncreaseEye gaze in individuals with high attachment anxiety
    Study

    n = 73

    Comparator
    Placebo
    Outcome group
    Social behavior and cognition · Nervous system and cognition
    Studied dose
    24 IU · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    Among participants who received oxytocin, as opposed to a placebo, only individuals with high attachment anxiety displayed more eye gaze and less mouth gaze towards facial expression, regardless of emotion valence.
    2 context sentences
    Summary · context
    We employed a placebo-controlled, double-blind, within-participants design.
    Summary · context
    The participants were 73 healthy individuals (41 men) who received a single dose of intranasal oxytocin (24 IU) on one occasion and a placebo dose on another occasion.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In healthy adults with high attachment anxiety, intranasal oxytocin reduced mouth gaze towards facial expressions compared with placebo.

    In plain wordsIn healthy adults with high attachment anxiety, nasal oxytocin reduced looking at the mouth of faces compared with placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseMouth gaze in individuals with high attachment anxiety
    Study

    n = 73

    Comparator
    Placebo
    Outcome group
    Social behavior and cognition · Nervous system and cognition
    Studied dose
    24 IU · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    Among participants who received oxytocin, as opposed to a placebo, only individuals with high attachment anxiety displayed more eye gaze and less mouth gaze towards facial expression, regardless of emotion valence.
    2 context sentences
    Summary · context
    We employed a placebo-controlled, double-blind, within-participants design.
    Summary · context
    The participants were 73 healthy individuals (41 men) who received a single dose of intranasal oxytocin (24 IU) on one occasion and a placebo dose on another occasion.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.